Trial Profile
Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary) ; Paclitaxel (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms LAPADO
- 14 Jan 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials database
- 12 Aug 2010 New trial record